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www.aacrBackground: The aim of this study is to identify serum biomarkers with classification and prognosis utility
for astrocytoma, in particular glioblastoma (GBM).
Methods: Our previous glioma microarray database was mined to identify genes that encode secreted or
membrane-localized proteins. Subsequent analysis was done using significant analysis of microarrays, fol-
lowed by reverse transcription-quantitative PCR (RT-qPCR) and immunohistochemical validation in tumor
tissues, ELISA and Western blot validation in sera, and correlation with survival of GBM patients.
Results: Significant analysis of microarrays identified 31 upregulated and 3 downregulated genes specif-
ically in GBMs. RT-qPCR validation on an independent set of samples confirmed the GBM-specific differential
expression of several genes, including three upregulated (CALU, CXCL9, and TIMP1) and two downregu-
lated (GPX3 and TIMP3) novel genes. With respect to osteopontin (OPN), we show the GBM-specific upre-
gulation by RT-qPCR and immunohistochemical staining of tumor tissues. Elevated serum OPN levels in
GBM patients were also shown by ELISA and Western blot. GBM patients with high serum OPN levels
had poorer survival than those with low serum OPN levels (median survival 9 versus 22 months respectively;
P = 0.0001). Further, we also show high serum TIMP1 levels in GBM patients compared with grade II/III
patients by ELISA and downregulation of serum GPX3 and TIMP3 proteins in GBMs compared with normal
control by Western blot analysis.
Conclusions: Several novel potential serum biomarkers of GBM are identified and validated. High serum
OPN level is found as a poor prognostic indicator in GBMs.
Impact: Identified serum biomarkers may have potential utility in astrocytoma classification and GBM
prognosis. Cancer Epidemiol Biomarkers Prev; 19(6); 1409–22. ©2010 AACR.Introduction
An immediate need in oncology is biomarkers, which
can be identified through simple noninvasive or less inva-
sive methods with the potential to identify cancer risk,
promote early diagnosis, grade accurately, and monitor
treatment response (1, 2). Serum seems to be a good choice
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Blood components are also highly dynamic that it can re-
flect the normal or abnormal status of an individual (1). Ge-
nomic and proteomic approaches using high-throughput
techniques have resulted in identification of several novel
genes and their products associated with cancer. Secreted
proteins can be used as circulating tumor markers for diag-
nosis and monitoring patient response to treatment.
Gliomas are the most common primary central ner-
vous system tumors of the brain. They include astrocyto-
mas, oligodendrogliomas, and oligoastrocytomas based
on type of cells they originate from, with the latter having
components of both cell types (3). Astrocytomas are fur-
ther divided into pilocytic astrocytoma (grade I), diffuse
astrocytoma (DA; grade II), anaplastic astrocytoma (AA;
grade III), and glioblastoma (GBM; grade IV), whereas
oligodendrogliomas are classified as diffuse oligodendro-
glioma (DO; grade II) and anaplastic oligodendroglioma
(AO; grade III). Pilocytic tumors are slow growing, non-
infiltrating, and usually cured by surgery. Although
malignant gliomas are represented by AA, AO, and1409
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DOI:10.1158/1055-9965.EPI-09-1077GBMs, patients with GBM have the worst prognosis with
a median survival <12 months despite advances in
surgery, radiation therapy, and chemotherapy (4). The
situation is further complicated by existing histopatholo-
gy-based classification, as it is likely to be subjective and
also suffers from considerable interobserver variation (5).
Accurate classification seems to be important as the treat-
ment modalities are substantially different between
grade III and IV patients (6, 7). Moreover, the existence
of subclass with varying responses to treatment within
similar histologic grades of glioma has been shown (8).
It is believed that classification based on gene signatures
has a good chance of achieving clinically relevant
subgroups. This warrants a need for identification of
more reliable biomarkers with extensive validation.
A number of serum biomarkers with multiple utility
for glioma have been reported (2). However, none of
these markers are approved for routine use for patients.
With an aim to identify new serum biomarkers that
could classify glioma grades more precisely and provide
prognostic value among GBM patients, we carried out
data mining of our glioma microarray database (9)
and identified genes that are located in the membrane
or secreted based on protein localization information
obtained from the SOURCE database as potential serum
biomarkers. Subsequent analysis by significant analysis of
microarrays (SAM), followed by reverse transcription-
quantitative PCR (RT-qPCR) validation, identified several
new GBM-specific serum markers. For selected genes, we
carried out additional validations. For one gene, that is,
osteopontin (OPN), the validation was also carried out by
immunohistochemical analysis using tissue sections and
ELISA using serum samples. Serum OPN level was
also correlated with patient survival. With this, we have
identified several secreted biomarkers, some of which are
potential serum markers of GBM.
Materials and Methods
Tumor samples
Tumor samples were collected from patients who were
operated at National Institute of Mental Health and Neu-
rosciences (NIMHANS) and Sri Satya Sai Institute of
Higher Medical Sciences (SSIHMS), Bangalore, India.
Normal brain tissue samples (anterior temporal lobe) ob-
tained during surgery for intractable epilepsy were used
as control samples. Informed consent from each patient
was obtained per IEC guidelines and approval. A total
of 118 samples, which included different grades of astrocy-
tomas: 8 DA (grade II), 26 AA (grade III), 44 GBM (grade
IV), oligodendroglioma including 7 DO (grade II) and 26
AO (grade III), and 7 normal brain samples were used for
real-time qPCR analysis in this study. Tissues were bi-
sected and one-half was snap-frozen in liquid nitrogen
and stored at −80°C until RNA isolation. The other half
was fixed in formalin and processed for paraffin sections,
and these tissues were used for histopathologic character-
ization and immunohistochemistry.Cancer Epidemiol Biomarkers Prev; 19(6) June 2010
American Asso Copyright © 2010 
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and RT-qPCR and Western blot analyses
The details, as previously described, are given in the
supplementary section (9-12).
Histopathology and immunohistochemistry
Histologic sections of normal brain and tumor tissues
were examined by light microscopy using hematoxylin
and eosin preparation. Tumor sections of diffusely infil-
trating astrocytomas were graded using the WHO grad-
ing scheme (13). A total of 82 cases (78 cases of diffusely
infiltrating astrocytoma and 4 control brain tissues) were
analyzed by immunohistochemistry. Paraffin sections
(4 μm) from the tumor tissue and control samples were
collected on silane-coated slides, and immunohistochem-
istry was done using an antibody against OPN (poly-
clonal: ab8448, Abcam, UK, diluted to 1:200). Antigen
retrieval was not required for OPN staining. After the ini-
tial processing steps, sections were incubated with the
primary antibody, overnight at 4°C. This was followed
by incubation with Super Sensitive poly–horseradish per-
oxidase detection system (QD440-XAK, Biogenex). 3,3′-
Diaminobenzidine (Sigma) was used as the chromogenic
substrate. The tumor sample, which showed significant
upregulation of OPN by qPCR, served as the positive
control. A negative control slide in which the primary an-
tibody was excluded was incorporated with each batch of
slides. Staining was scored on a scale of 0 to 2 (0, no stain-
ing; 1+, mild to moderate intensity; 2+, strong staining).
Only 2+ staining was considered for interpretation.
Serum collection, OPN, and TIMP1 ELISA
Serum collection and storage conditions are described
previously (12). OPN levels were determined in serum
samples using the human OPN immunoassay kit from
R&D Systems according to the manufacturer's protocol.
Human TIMP1 ELISA quantitation kit from R&D Sys-
tems was used to measure serum TIMP1 levels per the
manufacturer's instructions. More details can be seen in
the supplementary section.
Survival correlation with serum OPN levels
Newly diagnosed GBM patients (n = 30) who under-
went surgery in the two clinical centers (NIMHANS/
SSIHMS) were prospectively included. Approval by the
ethics committee and patient consent were obtained be-
fore initiation of the study. The patients were recruited
based on the following inclusion criteria: (a) adult pa-
tients (age between 18 and 65 years) with a supratentorial
lobar tumor; (b) patients who underwent maximal safe
resection of the tumor with minimal residue noted on
postoperative magnetic resonance imaging scan; and (c)
patients with postoperative Karnofsky's performance
score ≥70. The demographic data and clinical features
of these patients were noted. Blood was collected from
all patients preoperatively, and serum OPN levels were
assessed by the methods described above.Cancer Epidemiology, Biomarkers & Prevention
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diotherapy and chemotherapy. Radiotherapy was admin-
istered with a total dose of 59.4 Gy, given in 33 fractions
along with concomitant chemotherapy with temozola-
mide, administered at the dose of 100 mg/d, which
was continued daily for 45 days. Subsequently, five cy-
cles of cyclical chemotherapy with temozolamide at thewww.aacrjournals.org
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Patients were followed up clinically and with magnetic
resonance imaging. Re-surgery was offered for those
who developed symptomatic recurrence. The maximum
follow-up period was 34 months. At the end of study pe-
riod, 23 patients had expired and 7 were on follow up.Table 1. GBM-specific potential serum biomarkersSl no. Symbol Gene nameCancer Epidemiol Biomarkers Prev;
 ciation for Cancer Research
 on May 19, 2011nals.orgFold changeI. Genes overexpressed in grade 4 (GBM) compared with grades II and III (lower-grade astrocytomas)
1 SPP1 Secreted phosphoprotein 1
(OPN, bone sialoprotein I, early T-lymphocyte activation 1)
5.732 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) 3.51
3 TIMP1 Tissue inhibitor of metalloproteinase 1
(erythroid potentiating activity, collagenase inhibitor)
2.694 IGFBP2 Insulin-like growth factor binding protein 2, 36 kDa 2.49
5 FSTL1 Follistatin-like 1 1.70
6 CCL2 Chemokine (C-C motif) ligand 2 1.64
7 SILV Silver homologue (mouse) 1.60
8 PSG9 Pregnancy specific β-1-glycoprotein 9 1.60
9 PRL Prolactin 1.57
10 CYR61 Cysteine-rich, angiogenic inducer, 61 1.54
11 F11 Coagulation factor XI (plasma thromboplastin antecedent) 1.53
12 VEGF Vascular endothelial growth factor 1.52
13 CXCL14 Chemokine (C-X-C motif) ligand 14 1.51
14 PLAT Plasminogen activator, tissue 1.51
15 IGF2 Insulin-like growth factor 2 (somatomedin A) 1.50
16 GNRH1 Gonadotropin-releasing hormone 1 (leutinizing-releasing hormone) 1.49
17 SERPINE1 Serine (or cysteine) proteinase inhibitor, clade E
(nexin, plasminogen activator inhibitor type 1), member 1
1.4718 LAMP2 Lysosomal-associated membrane protein 2 1.47
19 SERPING1 Serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor),
member 1 (angioedema, hereditary)
1.4620 BDNF Brain-derived neurotrophic factor 1.44
21 APOC3 Apolipoprotein C-III 1.43
22 CXCL9 Chemokine (C-X-C motif) ligand 9 1.42
23 SERPINC1 Serine (or cysteine) proteinase inhibitor,
clade C (antithrombin), member 1
1.4124 CALU Calumenin 1.40
25 SPOCK2 Sparc/osteonectin, cwcv and kazal-like domains
proteoglycan (testican) 2
1.3826 TNC Tenascin C (hexabrachion) 1.38
27 IL16 Interleukin 16 (lymphocyte chemoattractant factor) 1.34
28 LAD1 Ladinin 1 1.31
29 AP2A2 Adaptor-related protein complex 2, α2 subunit 1.30
30 IL6 Interleukin 6 (interferon, β2) 1.29
31 MAPT Microtubule-associated protein τ 1.25II. Genes overexpressed in grades II and III (lower-grade astrocytomas) compared with grade IV (GBM)
1 SPARCL1 SPARC-like 1 (mast9, hevin) 3.27
2 TIMP3 Tissue inhibitor of metalloproteinase 3
(Sorsby fundus dystrophy,pseudoinflammatory)
2.273 GPX3 Glutathione peroxidase 3 (plasma) 2.0219(6) June 2010 1411
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15 months.
Results
Analysis of secreted or plasma membrane–
associated genes in astrocytoma microarray
expression profile database
With the idea that genes that encode protein located in
the plasmamembrane or secreted are likely to be potential
serum biomarkers, we analyzed our recently published
microarray data (9). Using protein localization informa-
tion from the SOURCE database, we identified 226 such
genes from a total of 18,981 genes that were spotted in
the microarray. In the next step, we used SAM to find
genes that are differentially expressed between GBM
and lower-grade astrocytomas (grade II/III). Of the total
of 34 genes that are differentially expressed, 31 were upre-
gulated in GBMs as against lower-grade astrocytomas
(grade II/III) and 3 were downregulated in GBM as
against lower-grade astrocytomas (grade II/III) were
identified (Table 1). To get a visual appreciation as well
as to see the substructure of the data containing expressionCancer Epidemiol Biomarkers Prev; 19(6) June 2010
American Asso Copyright © 2010 
cebp.aacrjourDownloaded from values of 34 genes, we carried out hierarchical cluster
analysis using the TMEV software (Fig. 1). Besides many
novel genes, the list included genes such asVEGF, IGFBP2,
and CHI3L1, which were previously reported as GBM
serum markers.
Validation of GBM-specific secreted biomarkers
Among 34 potential secretory biomarkers that can dis-
criminate GBM from lower-grade astrocytomas (AA and
DA), some of the genes have already been reported,
whereas many were novel and relatively less studied.
Some of the genes that were previously reported, such
as CHI3L1, IGFBP2, VEGF, TNC, and FSTL1, were vali-
dated in the present study (data not shown). We have re-
cently reported FSTL1 as a GBM-specific upregulated
marker (9). The novel genes that were validated in
this study are CALU, CXCL9, TIMP1, GPX3, and TIMP3
(Table 2); other important genes that we have validated
are SERPINE1, PLAT, IL6, and OPN (Table 2).
A novel gene upregulated in GBM is calumenin
(CALU), which is a calcium-binding protein located in
the endoplasmic reticulum and involved in protein fold-
ing and sorting (14). We found the transcript levels ofCancer Epid
ciation for Cancer
 on May 1nals.orgFigure 1. One-way hierarchical cluster analysis
of SAM-identified genes using the TMEV
software to see the data substructure.
Normalized, log 2–transformed expression
ratios of SAM-identified differentially regulated
genes between GBMs (grade IV) and
lower-grade astrocytomas (grades II and III)
were subjected to one-way hierarchical
clustering using the TMEV software.
A dual-color code was used, with red and green
indicating upregulation and downregulation,
respectively, in a particular glioma sample
compared with normal brain tissue. Subclusters
A and B represent genes that are upregulated
and downregulated respectively in GBMs
compared with lower-grade astrocytoma
(grades II and III).emiology, Biomarkers & Prevention
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DOI:10.1158/1055-9965.EPI-09-1077CALU to be significantly upregulated to very high levels
in GBMs (mean log 2 ratio 1.26 ± 1.07) compared with
DA, AA, DO, AO, and normal brain samples (mean log
2 ratios −0.06 ± 1.01, −1.20 ± 0.71, −1.40 ± 0.78, −0.98 ±
0.88, and 0.00 ± 1.44, respectively; Fig. 2A; Table 2). An-
other interesting gene found upregulated in a majority
of GBMs was CXCL9, a member of the chemokine
family, which is a group of small structurally related mo-
lecules that regulates cell trafficking of various types of
leukocytes through interactions with a subset of seven-
transmembrane, G protein-coupled receptors. CXCL9
transcripts were found upregulated significantly in
GBMs (mean log 2 ratio 3.74 ± 1.94) compared with
AA, DO, AO, and normal brain samples (mean log 2 ra-
tios 2.10 ± 2.30, 0.53 ± 2.64, 1.28 ± 2.14, and 0.00 ± 1.91,
respectively; Fig. 2C; Table 2).
Two novel genes that were found to be downregulated
in GBMs are GPX3 and TIMP3. GPX3 is a secreted mem-
ber of glutathione peroxidase family involved in reduc-
tion of hydrogen peroxide, thereby protecting cells from
oxidative damage. GPX3 transcripts were found down-
regulated significantly in GBMs (mean log 2 ratio 2.20 ±
1.59) compared with AA and normal brain samples
(mean log 2 ratios 4.02 ± 1.70 and 0.00 ± 1.63, respectively;
Fig. 2G; Table 2). However, oligodendroglioma grade
II/DO (mean log 2 ratio of 0.99 ± 2.33) and grade III/
AO (mean log 2 ratio of 2.27 ± 1.36) also had an expression
pattern similar toGBM (Fig. 2G; Table 2).We also analyzed
serum GPX3 protein levels by Western blot (Fig. 3A).
Statistical analysis usingMann-Whitney test revealed that
the serum GPX3 protein level, as measured by intensity,
in GBM sera (mean intensity 0.91 ± 0.24) was significantly
(P = 0.048) less compared with that of normal sera (mean
intensity 1.11 ± 0.21).
The transcript levels of tissue inhibitor of metalloprotei-
nase 3 (TIMP3) was found to be downregulated signifi-
cantly in GBMs (mean log 2 ratio −1.53 ± 1.04) compared
withDA,AA, and normal brain samples (mean log 2 ratios
−0.31 ± 0.50,−0.60 ± 0.74, and 0.00 ± 1.57, respectively; Fig.
2H; Table 2). However, oligodendroglioma grade 2/DO
(mean log 2 ratio of −1.22 ± 0.72) and grade 3/AO (mean
log 2 ratio of −1.19 ± 1.05) also had an expression pattern
similar to GBM (Fig. 2H; Table 2). We also analyzed the
serum TIMP3 protein levels byWestern blot (Fig. 3B). Sta-
tistical analysis usingMann-Whitney test revealed that the
serum TIMP3 protein level, as measured by intensity, in
GBM sera (mean intensity 0.67 ± 0.28) was less compared
with that of normal sera (mean intensity 1.00 ± 0.48),
which showed a tendency toward statistical significance
(P = 0.068). Thus, these two genes,GPX3 and TIMP3, seem
to discriminate GBM from lower-grade astrocytomas (AA
and DA) but not oligodendrogliomas (AO and DO).
We have also confirmed GBM-specific expression of
four more relatively less studied genes. The first gene is
serine proteinase inhibitor, clade E, member 1 (SERPINE1), al-
so known as plasminogen activator inhibitor, type 1 (PAI-1).
SERPINE1 was found to be upregulated significantly in
GBMs compared with DA, AA, DO, and AO (Fig. 2B;www.aacrjournals.org
American Asso Copyright © 2010 
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nificantly in GBMs compared with DA, AA, DO, AO,
and normal samples (Fig. 2D; Table 2). We have also
validated GBM-specific upregulation of TIMP1 at the
level of serum TIMP1 protein by ELISA (Fig. 3C). Com-
parisons of serum TIMP1 levels were made between
different grades of astrocytoma and normal sera. Krus-
kal-Wallis ANOVA followed by post hoc Tukey's Honest
Significant Difference (HSD) test showed that the differ-
ence between GBM and DA and AA to be significant (P
< 0.0001 and P < 0.0001, respectively). The mean serum
TIMP1 level in the GBM sera was 159.96 ± 55.40 com-
pared with 61.58 ± 26.41 in AA and 63.14 ± 25.45 in
DA. However, the serum TIMP1 levels in normal indivi-
duals (mean 173.33 ± 55.08) was not different from that of
GBM patients. Because the GBM samples used for this
analysis (n = 52) underwent uniform treatment protocol
and were prospectively followed up, we analyzed the
survival utility of TIMP1. The median survival among
GBM patients in the group with serum TIMP1 levels
>195 ng/mL was less than the group with TIMP1 level
lesser than 195 ng/mL (11 months versus 17 months,
respectively). However, these data were found to be
statistically not significant (data not shown).
The third gene found to be upregulated in GBMs is
plasminogen activator, tissue type (PLAT; t-PA). PLAT tran-
scripts were found to be significantly upregulated in
GBMs compared with lower-grade astrocytomas (DA
and AA) as well as oligodendrogliomas (DO and AO;
Fig. 2F; Table 2). Interleukin 6 (IL6) was the fourth gene
found to be significantly upregulated in GBMs as against
DA, AA, DO, AO, and normal samples (Fig. 2E; Table 2).
We have also measured the transcript levels of these
eight genes in glioma-derived cell lines. In principle, all
the eight genes were found to show similar GBM-specific
differential regulation, like GBM tissue samples, com-
pared with normal brain samples in most glioma cell
lines (Supplementary Fig. S1).
OPN is a GBM-specific serum biomarker with
prognostic value
Although there were few reports of OPN upregulation
in GBM, we thought that a thorough investigation of
OPN regulation in different grades of glioma is needed.
We carried out detailed analysis of OPN at RNA and pro-
tein levels in tumor tissue and serum OPN levels in dif-
ferent grades of astrocytoma as well as its effect on
patient survival. OPN transcript exists in three isoforms,
a, b, and c (corresponding to transcript variants 1, 2, and
3, respectively), which arises due to differential splicing.
All the three isoforms were found to be upregulated sig-
nificantly in GBMs compared with DA, AA, DO, AO,
and normal samples, except DA versus GBM in the case
of OPN tv1 (Fig. 4A-C; Table 2). Interestingly, when
glioma-derived cell lines were tested for OPN transcript
levels, we found the OPN transcript variant 2 alone to
be upregulated in most glioma cell lines, whereas
the transcript levels of variants 1 and 3 were actuallyCancer Epidemiol Biomarkers Prev; 19(6) June 2010 1413
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Table 2. Statistical analysis of regulation of potential GBM-specific serum biomarkers in different glioma grades
Sl no. Gene Cutoff
log 2
ratios
Normal DO II DA II AO III AA III GBM Post
hoc P*
Kruskal-
Wallis test
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
χ2 P
I. GBM upregulated genes
1 CXCL9 2.50 14.28%
(1/7)
0.00 ±
1.91
14.28%
(1/7)
0.53 ±
2.64
50.00%
(4/8)
2.78 ±
2.35
26.92%
(7/26)
1.28 ±
2.14
34.61%
(9/26)
2.10 ±
2.30
84.09%
(37/44)
3.74 ±
1.94
ε = 0.0007 29.93 <0.0001
ω = 0.006
¢ = 0.0002
π = 0.0365
2 TIMP1 2.00 14.20%
(1/7)
0.00 ±
1.84
0% (0/7) −2.93 ±
1.35
0%
(0/8)
−1.95 ±
1.61
11.50%
(3/26)
−1.54 ±
2.24
0%
(0/26)
−2.30 ±
1.28
68.10%
(30/44)
2.36 ±
1.79
α = 0.03 69.38 <0.0001
δ = 0.028
ε = 0.018
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
3 SERPINE1 1.00 42.80%
(3/7)
0.00 ±
2.47
0% (0/7) −3.25 ±
1.41
0%
(0/8)
−1.50 ±
1.39
23.10%
(6/26)
−1.29 ±
2.88
11.50%
(3/26)
−1.45 ±
1.69
68.10%
(30/44)
2.09 ±
2.55
ω < 0.0001 52.69 <0.0001
λ = 0.0017
¢ < 0.0001
π < 0.0001
4 IL6 1.00 42.80%
(3/7)
0.00 ±
2.21
0% (0/7) −1.57 ±
1.33
0%
(0/8)
−0.96 ±
1.16
7.60%
(2/26)
−1.82 ±
1.48
7.60%
(2/26)
−1.05 ±
1.63
65.90%
(29/44)
2.10 ±
2.00
ε = 0.0427 59.62 <0.0001
ω < 0.0001
λ = 0.0002
¢ < 0.0001
π < 0.0001
5 CALU 0.56 42.85%
(3/7)
0.00 ±
1.44
0% (0/7) −1.40 ±
0.78
25.00%
(2/8)
−0.06 ±
1.01
7.69%
(2/26)
−0.98 ±
0.88
0%
(0/26)
−1.20 ±
0.71
79.54%
(35/44)
1.26 ±
1.07
δ = 0.0437 70.04 <0.0001
ε = 0.0206
ω < 0.0001
μ = 0.0432
λ = 0.0069
¢ < 0.0001
π < 0.0001
6 PLAT 0.56 28.57%
(2/7)
0.00 ±
1.73
0% (0/7) −3.02 ±
0.82
12.50%
(1/8)
−2.25 ±
1.86
3.84%
(1/26)
−2.20 ±
1.67
3.84%
(1/26)
−2.40 ±
1.46
72.72%
(32/44)
0.90 ±
1.28
α = 0.0027 64.66 <0.0001
β = 0.0426
γ = 0.0079
δ = 0.0027
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Table 2. Statistical analysis of regulation of potential GBM-specific serum biomarkers in different glioma grades (Cont'd)
Sl no. Gene Cutoff
log 2
ratios
Normal DO II DA II AO III AA III GBM Post
hoc P*
Kruskal-
Wallis test
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
Percent‐
age
Mean
log 2
ratios
± S.D
χ2 P
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
7A OPN tv 1 2.00 0% (0/4) 0.00 ±
1.07
0%
(0/7)
−0.86 ±
0.86
25.00%
(2/8)
1.43 ±
0.83
19.20%
(5/26)
0.53 ±
1.87
7.60%
(2/26)
0.19 ±
1.27
77.20%
(34/44)
2.97 ±
1.62
ε = 0.0041 54.48 <0.0001
η = 0.0488
ω < 0.0001
¢ < 0.0001
π < 0.0001
7B OPN tv 2 4.00 0% (0/4) 0.00 ±
1.08
0%
(0/7)
1.67 ±
1.07
12.50%
(1/8)
1.59 ±
2.01
26.90%
(7/26)
2.94 ±
1.75
7.60%
(2/26)
2.19 ±
1.24
97.70%
(43/44)
6.34 ±
1.36
γ = 0.0039 78.25 <0.0001
ε < 0.0001
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
7C OPN tv 3 1.00 25.00%
(1/4)
0.00 ±
1.11
0%
(0/7)
−1.94 ±
1.42
0%
(0/8)
−0.15 ±
0.90
15.30%
(4/26)
−0.30 ±
1.64
23.10%
(6/26)
−0.44 ±
1.84
90.90%
(40/44)
3.32 ±
1.66
ε = 0.0024 67.38 <0.0001
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
II. GBM downregulated genes
8 GPX3 3.00 100%
(7/7)
0.00 ±
1.63
71.42%
(5/7)
0.99 ±
2.33
37.50%
(3/8)
3.74 ±
1.61
80.00%
(21/26)
2.27 ±
1.36
23.07%
(6/26)
4.02 ±
1.70
75.0%
(33/44)
2.20 ±
1.59
β = 0.0003 34.00 <0.0001
γ = 0.0160
δ < 0.0001
ε = 0.0145
η = 0.0170
Φ = 0.0004
ζ = 0.0024
π = 0.0002
9 TIMP3 −0.56 57.14%
(4/7)
0.00 ±
1.57
71.42%
(5/7)
−1.22 ±
0.72
12.50%
(1/8)
−0.31 ±
0.50
57.69%
(15/26)
−1.19 ±
1.05
38.46%
(10/26)
−0.60 ±
0.74
79.54%
(35/44)
−1.53 ±
1.04
ε = 0.0027 22.56 0.0004
λ = 0.0188
π = 0.0073
*Tukey's post hoc test showing a significant P value: α, normal vs DO; β, normal vs DA; γ, normal vs AO; δ, normal vs AA; ε, normal vs GBM; η, DO vs DA; Ψ, DO vs AO; Φ, DO
vs AO; ω, DO vs GBM; Ω, DA vs AO; μ, DA vs AA; λ, DA vs GBM; ζ, AO vs AA; ¢, AO vs GBM; π, AA vs GBM.
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DOI:10.1158/1055-9965.EPI-09-1077downregulated in glioma cell lines compared with nor-
mal brain controls (Fig. 4D-F).
We also analyzed the OPN protein levels by immuno-
histochemistry in astrocytoma tissue sections. We found
OPN protein staining to be cytoplasmic and accentuated
at the surface of the tumor cells (Fig. 5). The macrophages
infiltrating the tumor were also stained. In addition to the
tumor cells and macrophages, the interstitial stroma
stained prominently in several examined cases. OPN ex-
pression was pronounced around vessels and at the bor-
der of necrosis. Upon semiquantitative analysis of tumor
cell positivity of OPN, we found that a majority of GBM
(70%; 33 of 44) had immunopositive cells compared with
AA (23.0%; 6 of 26) and DA (0.0%; 0 of 8). However,
staining of the extracellular matrix was extensive andwww.aacrjournals.org
American Asso Copyright © 2010 
cebp.aacrjourDownloaded from seen in 95.5% (42 of 44) of GBM and 50% cases of DA
and AA. It was observed that the extent of staining of
the extracellular matrix was diffuse and more extensive
in GBM tumors compared with cases of DA or AA
(Fig. 5). In the control samples, there was no staining of
neurons, astrocytes, oligodendrocytes, neuropil, and stro-
ma as well as the parenchymal vessels.
The levels of OPN protein in serum samples belonging
to different grades of astrocytoma and normal controls
were measured by ELISA (Fig. 6A). Comparisons of se-
rum OPN levels were made between different grades of
astrocytoma and normal controls as well as between dif-
ferent grades. Kruskal-Wallis ANOVA followed by post
hoc Tukey's HSD test showed the difference between
GBM and normal controls (P = 0.001), GBM and DAFigure 2. Scatter plots of the transcript levels of novel secretory biomarkers, which can potentially discriminate GBM from astrocytoma grades II/III
and oligodendroglioma grades II/III. Log 2–transformed gene expression ratios obtained from real-time RT-qPCR analysis of RNA derived from tumor
tissue samples (as indicated) are plotted for CALU (A), SERPINE1 (B), CXCL9 (C), TIMP1 (D), IL6 (E), PLAT (F), GPX3 (G), and TIMP3 (H). Each dot represents
a data derived from one sample. In each sample, fold change in gene expression is calculated over its mean expression in normal brain samples. An
increase or decrease in gene expression at a particular cutoff (horizontal dotted line) based on the expression pattern of a specific gene across different
grades of tumors was considered significant. Horizontal line in each group designates the median value.Figure 3. Analysis of serum TIMP3,
GPX3, and TIMP1. A, total serum
protein (5 μL) from normal healthy
controls and GBM patients was
subjected to Western blot analysis for
TIMP3.B,albumin/IgGdepletedserum
protein (50 μg) from normal healthy
controls and GBM patients was
subjected to Western blot analysis for
GPX3. C, serum levels of TIMP1
(ng/mL) in normal controls (n = 34),
DAs (n = 13), AAs (n = 13), and GBMs
(n = 52) are plotted. Horizontal line in
each group designates the mean
value. Statistical significance was
tested by Kruskal-Wallis one-way
ANOVA using SPSS 15.0 forWindows
software.Cancer Epidemiol Biomarkers Prev; 19(6) June 2010 1417
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DOI:10.1158/1055-9965.EPI-09-1077Figure 4. Scatter plot of transcript levels of OPN in different grades of astrocytoma and glioma cell lines. A to C, log 2–transformed gene expression
ratios obtained from real-time RT-qPCR analysis of RNA derived from tumor tissue samples (as indicated) are plotted for OPN tv1 (transcript variant 1; A),
tv2 (B), and tv3 (C). Each dot represents a data derived from one sample. In each sample, fold change in gene expression is calculated over its mean
expression in normal brain samples. An increase or decrease in gene expression at a particular cutoff (horizontal dotted line) based on the expression
pattern of a specific gene across different grades of tumors was considered significant. Horizontal line in each group designates the median value.
D to F, log 2–transformed gene expression ratios obtained from real-time RT-qPCR analysis of RNA derived from different glioma cell lines (black bars,
left to right order of cell lines: LN-18, LN-229, U-138, U-251, U-343, U-373, U-87) are plotted for OPN tv1 (transcript variant 1; D), tv2 (E), and tv3 (F).
The gray bars represent the normal brain control samples used in this experiment. Each bar represents a data derived from one sample. In each sample,
fold change in gene expression is calculated over its mean expression in normal brain samples.Cancer Epidemiol Biomarkers Prev; 19(6) June 2010 Cancer Epidemiology, Biomarkers & Prevention
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DOI:10.1158/1055-9965.EPI-09-1077(P = 0.046), and GBM and AA (P = 0.008) to be signifi-
cant. The mean serum OPN level (ngm/mL) in GBM
was 31.54 ± 28.98 compared with 17.38 ± 7.91 in AA,
13.79 ± 4.56 in DA, and 11.70 ± 7.26 in normal control.
We have also validated serum OPN levels between
normal healthy individuals and GBM patients by
Western blot analysis (Fig. 6B). Statistical analysis using
Mann-Whitney test revealed the serum OPN protein
level, as measured by intensity, in GBM sera (mean inten-
sity 1.40 ± 0.43) to be more significant compared with
that of normal sera (mean intensity 1.00 ± 0.41; P = 0.037).
A subset of GBM patients (n = 30) who underwent uni-
form treatment protocol and were prospectively followed
up was used for survival analysis (Fig. 6C). The serum
OPN level of 20 ng/mL was found to significantly corre-
late with the survival. The median survival among GBM
patients in the group with serum OPN levels >20 ng/mL
was significantly less than in that group with ≤20 ng/mL
(9 months versus 21 months, respectively; P ≤ 0.0001;
univariate analysis). On multivariate analysis, taking intowww.aacrjournals.org
American Asso Copyright © 2010 
cebp.aacrjourDownloaded from consideration other factors like age, cognitive dysfunc-
tion, and p53 status, a serum OPN level cutoff of 20 ng/mL
was still independently significant (P = <0.0001; Cox re-
gression analysis, forward Walds). This indicates that
the preoperative serum OPN level is a definite prognostic
indicator in GBM.
Discussion
In this study, we have used a unique approach to
screen our cancer microarray database to identify poten-
tial secreted biomarkers. In the first step, we pulled out
expression data of all the genes whose protein products
localized either in the plasma membrane or were secret-
ed. Using SAM, we identified GBM-specific serum mar-
kers and subsequently validated many of them. Some of
the genes identified in this screen, such as CHI3L, IGFBP2,
and VEGFA, have been previously reported as GBM-
specific serum markers with prognostic value (15-18).
In our study, we could also show the GBM-specificFigure 5. Immunohistochemical
validation of OPN overexpression
in astrocytoma. Sections from
DA-negative for staining (A),
DA-positive for staining (B),
AA—negative for staining (C),
AA—positive for staining (D), and
secondary GBMs and primary
GBM—positive for staining
(E and F) were stained for OPN.Cancer Epidemiol Biomarkers Prev; 19(6) June 2010 1419
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DOI:10.1158/1055-9965.EPI-09-1077expression of the transcripts of these genes by RT-qPCR
(data not shown). These previous findings from others
and the real-time RT-qPCR validation from our study
provide support to our methodology of detecting serum
biomarkers.
We have also identified few novel genes that are spe-
cifically regulated in GBM. CALU is a novel gene found
upregulated specifically in GBM but not in low-grade
astrocytomas and oligodendrogliomas. CALU belongs
to a family of multiple EF-hand proteins that includeCancer Epidemiol Biomarkers Prev; 19(6) June 2010
American Asso Copyright © 2010 
cebp.aacrjourDownloaded from reticulocalbin, ERC-55, and Cab45, and human CALU
has been shown to be secreted (19). However, the signif-
icance of upregulation of CALU in GBMs is not known.
CXCL9, a member of chemokine family, was found in
this study as an upregulated GBM-secreted biomarker.
Although CXCL9 and other members have been shown
to be upregulated in other cancers, we report for the
first time that CXCL9 is a GBM-specific secretory marker
(20, 21). It is interesting to note that although our micro-
array data had other CXCL genes, CXCL10, CXCL12, andCancer Epidemiology,
ciation for Cancer Research
 on May 19, 2011nals.orgFigure 6. Scatter plot of serum
OPN levels and its correlation
with patient survival. A, serum
levels of OPN (ng/mL) in normal
controls (n = 22), DAs (n = 12),
AAs (n = 36), and GBMs (n = 78).
The horizontal line in each group
designates the mean value. B,
total serum protein (2.5 μL) from
normal healthy controls and GBM
patients was subjected to
Western blot analysis for OPN.
C, Kaplan-Meier survival
estimates for 30 GBM patients
are calculated for their serum
OPN levels. Survival curves for
the groups positive and negative
for OPN in univariate analysis are
shown. Cases that were low for
serum OPN levels (≤20 ng/mL;
black line; n = 19) had a better
survival than the cases that were
high for serum OPN levels
(>20 ng/mL; gray line; n = 11;
P = 0.0001).Biomarkers & Prevention
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DOI:10.1158/1055-9965.EPI-09-1077CXCL13, only CXCL9 was identified by SAM analysis,
suggesting the specific upregulation of CXCL9 from the
chemokine family in GBMs.
We also identified two genes, GPX3 and TIMP3,
specifically downregulated in GBMs compared with
lower-grade astrocytomas (DA and AA) but not in oligo-
dendrogliomas (DO and AO). We show our initial micro-
array data–based finding that these two genes are
downregulated in GBM by ELISA and Western blot.
GPX3 is also called as extracellular or plasma glutathione
peroxidase and is the only member of glutathione perox-
idase family that is secreted. Although our microarray
data had other members of the GPX family, GPX1,
GPX4, and GPX6, only GPX3 was identified by SAM,
which showed specific upregulation in GBMs. These
two markers, GPX3 and TIMP3, are of value in differenti-
ating oligodendroglioma grade 2 and 3 from astrocytoma
grade 2 and 3, as these markers were overexpressed in
both DO and AO (Fig. 2G and H; Table 2).
TIMP1 and TIMP3, members of the tissue inhibitor of
metalloproteases, were found differentially regulated in
GBMs. Matrix metalloproteinases, many of which are
overexpressed in malignant tumors, including GBM, are
inhibited by TIMPs. It is suggested that a balance between
the matrix metalloproteinases and TIMPs may contribute
to malignant behavior of many cancers. Although TIMPs
are known for their inhibition of tumor malignancy, a
differential role for some of TIMPs has been reported. For
example, TIMP1 has been shown to stimulate proliferation
of many cell types (22-25). In good correlation, our data
clearly provide evidence for the GBM-specific upregula-
tion of TIMP1.We have found that TIMP1 transcripts were
upregulated severalfold in GBMs compared with other
grades of astrocytoma and oligodendroglioma (Fig. 2D).
In addition, serum TIMP1 levels are elevated in GBM pa-
tients compared with lower-grade astrocytoma patients
(Fig. 3C). Unlike TIMP1, TIMP3 has been shown to pro-
mote apoptosis possibly through stabilization of tumor
necrosis factor α receptors (26-28). Accordingly, we found
TIMP3 transcripts downregulated significantly in GBMs
compared with lower-grade astrocytomas (Fig. 2H).
Another interesting gene we have validated was OPN,
which is a member of the SIBLING (small integrin-binding
ligand N-linked glycoprotein) family and has been found
to be overexpressed in many cancers and associated with
tumor progression and metastasis (29-32). High levels of
OPN expression correlate with tumor invasion, progres-www.aacrjournals.org
American Asso Copyright © 2010 
cebp.aacrjourDownloaded from sion, or metastasis in multiple cancers. Studies show that
OPN mediates the molecular mechanisms that determine
metastatic spread, such as prevention of apoptosis, extra-
cellular matrix proteolysis and remodeling, cell migration,
evasion of host-immune cells, and neovascularization.
Transcriptional regulation of OPN is complex and in-
volves multiple pathways, including AP-1, Myc, v-Src,
Runx/CBF, TGF-β/BMPs/Smad/Hox, and Wnt/β-cate-
nin/APC/GSK-3β/Tcf-4 (29). OPN expression has been
found to correlate with tumor progression in astrocytoma
with high levels in GBM (33-35). OPN levels detected by
immunohistochemistry identified that high cytoplasmic
OPN expression correlates with poor patient survival
(36). Although serum OPN levels have been shown to cor-
relate with patient survival in other cancers (37), there has
been no such report with respect to glioma. Our results
show that OPN is upregulated both at the RNA and pro-
tein levels only in GBM. Further, serum OPN levels were
high in GBM and are poor prognostic indicators. Our find-
ings are also supported by recently published TCGA data,
in which we found that seven of nine genes (CALU,
CXCL9, IL6, PLAT, TIMP1, OPN, and SERPINE1) are sim-
ilarly regulated (38). Thus, we provide evidence for ana-
lyzing large microarray data through bioinformatics
methods to find potential serum/secreted biomarkers.
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